Hypoxia targeting lutetium-177-labeled nitroimidazole-decorated gold particles as cancer theranostic nanoplatforms

Considering the role of hypoxia in cancer progression and poor prognosis, hypoxia-centric theranostic approaches may have immense potential in clinical cancer management. We have successfully developed a hypoxia-selective theranostic nanoplatform, which can be used to deliver a therapeutic dose of r...

Full description

Saved in:
Bibliographic Details
Published inMaterials advances Vol. 3; no. 4; pp. 1993 - 1999
Main Authors Mittal, Sweety, Sharma, Rohit, Sarma, H. D, Mallia, Madhava B
Format Journal Article
LanguageEnglish
Published 21.02.2022
Online AccessGet full text

Cover

More Information
Summary:Considering the role of hypoxia in cancer progression and poor prognosis, hypoxia-centric theranostic approaches may have immense potential in clinical cancer management. We have successfully developed a hypoxia-selective theranostic nanoplatform, which can be used to deliver a therapeutic dose of radiation to the hypoxic tumor tissue through systemic administration. In addition to delivering a radiation dose to the hypoxic tumor tissue, the versatile nanoplatform developed can also be used to load radiosensitizers or chemotherapeutic drugs to enhance the therapeutic effect. Theranostic 177 Lu-labeled nitroimidazole-decorated gold nanoparticles showed ∼9-fold uptake in CHO cells under hypoxic conditions compared to normoxic conditions.
Bibliography:10.1039/d1ma01123e
Electronic supplementary information (ESI) available. See DOI
ISSN:2633-5409
2633-5409
DOI:10.1039/d1ma01123e